Alterity Therapeutics Share Price and Company Fundamentals
Last traded: Today at 5:10 AM
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Key Metrics
PE ratio
-
PB ratio
1.60
Dividend yield
-
Beta
-0.02
Market cap
$87.00M
Enterprise value
$33.17M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Full time employees | 9 |
| Website | https://alteritytherapeutics.com |
| Mailing address | 350 Collins Street Suite 4 Level 14 Melbourne VIC 3000 Australia |
| Phone / Fax | 61 3 9349 4906 / 61 3 9349 4906 |
Dividends
More: Alterity Therapeutics Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Alterity Therapeutics paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.ATH dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Alterity Therapeutics.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Dr. David A. Stamler M.D. | CEO & Director | 64 | |
| Ms. Abby Macnish Niven B.Com., B.Sc., C.F.A. | CFO & Company Secretary | 42 | |
| Dr. Rudolph Emile Tanzi Ph.D. | Chief Scientific Advisor and Member of Research & Development Advisory Board | 67 | |
| Dr. Steven D. Targum M.D. | Chief Medical Advisor | ||
| Dr. Robert Cherny | Head of Research |
Profitability and management effectiveness
Profit margin
-223.35%
Operating margin
-185.73%
Return on assets
-28.09%
Return on equity
-43.23%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Alterity Therapeutics is 87.00M and its enterprise value is 33.17M. The enterprise value to revenue ratio of ATH is 6.10. The enterprise value to EBITDA ratio of ATH is -2.27.
Companies similar to Alterity Therapeutics (ATH)
Alterity Therapeutics (ASX:ATH) Frequently Asked Questions
1. What is Alterity Therapeutics's Stock Symbol?
Alterity Therapeutics trades on ASX under the ticker symbol "ATH".
2. What is Alterity Therapeutics's stock price today?
One share of ATH stock can currently be purchased for approximately $0.008.
3. How can I contact Alterity Therapeutics?
Alterity Therapeutics's mailing address is 350 Collins Street Suite 4 Level 14 Melbourne VIC 3000 Australia. The company can be reached via phone at 61 3 9349 4906.
4. What is Alterity Therapeutics's official website?
The official website of Alterity Therapeutics is https://alteritytherapeutics.com.